Clinical trials: Treatment Resistant Major Depressive Disorder
Depressive Disorder, Major, Metabolic Syndrome X
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid…
- Trial name
- NCT00671515
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Joseph Calabrese, MD
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Sevoflurane for Treatment-Resistant Depression
This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.
- Trial name
- NCT05008939
- Testing
- Sevoflurane
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Major Depressive Disorder, Treatment Resistant Depression
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory.
- Trial name
- NCT05680220
- Testing
- Neurostimulation System (NSS): Active Setting
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Klaus Martiny
Major Depressive Disorder
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
- Trial name
- NCT01640080
- Testing
- Esketamine
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Treatment-Resistant
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
The overarching aim of this research is to determine the acute effects of ketamine on brain glutamate, functional connectivity and cerebral blood flow in treatment-resistant depression, explore whether the effects are attenuated…
- Trial name
- GO-MARK (NCT04977674)
- Testing
- Naltrexone, Ketamine
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- King's College London
Major Depressive Disorder, Treatment Resistant Depression
Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression
According to the World Health Organization, MDD is attributed as the leading cause of disability worldwide, leaving 300 million individuals affected.
- Trial name
- NCT03977038
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Depressive Disorder
Cerebral Neuroinflammation During Major Depressive Episode
the investigators make the following assumptions: 1) neuroinflammation in MDD can be measured by the [18 F ] DPA- 714 ; 2) it is accompanied by anatomical and functional changes in the frontal subcortical loops, strongly involved…
- Trial name
- InflaDep (NCT03314155)
- Testing
- Cerebral neuroinflammation evaluation
- Where
- 4 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Moderate Depression, Major Depressive Disorder
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
The aim of this study is to explore the effectiveness and safety of different doses of neural regulation under the guidance of pBFS technology in improving symptoms in patients with moderate to severe depressive disorders.
- Conditions
- Moderate Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT06112652
- Testing
- 4 session rTMS, 6 session rTMS, 8 session rTMS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changping Laboratory
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder
Major Depressive Disorder (MDD) is one of the most prevalent mental illnesses in North America, in which 30% - 40% fail to respond to conventional treatment.
- Trial name
- NCT01515215
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression (TRD), Late Life Depression (LLD)
Lumateperone for Late-Life Depression
The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S.
- Conditions
- Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
- Trial name
- IRL Grey-C (NCT07623135)
- Testing
- Lumateperone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eric Lenze
Treatment Resistant Depression, Major Depressive Disorder
Predictors of Intravenous Ketamine Response in TRD
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT05625555
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abraham Nunes
Major Depressive Disorder
High Dose Accelerated iTBS for Depression
This trial will compare active intermittent theta burst stimulation (iTBS) rTMS in an accelerated treatment schedule (8 treatment sessions per day for 5 days) to a placebo control.
- Trial name
- NCT04255784
- Testing
- Active iTBS
- Where
- 2 sites in Canada
- Volunteers
- 228 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Recurrent Depressive Disorder
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression
Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.
- Conditions
- Major Depressive Disorder, Recurrent Depressive Disorder, Bipolar Disorder
- Trial name
- STHYM (NCT01973478)
- Testing
- DBS
- Where
- 5 sites in France
- Volunteers
- 9 people
- Sponsor
- Rennes University Hospital
Major Depressive Disorders
The Effects of Transcranial Magnetic Stimulation on Retina and Choroidal Structures
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMSEYE (NCT06615804)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Major Depressive Disorder
A Study of Ketamine in Patients With Treatment-resistant Depression
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
- Trial name
- NCT01627782
- Testing
- Ketamine
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
VA Aripiprazole vs Esketamine for Treatment Resistant Depression
This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs.
- Trial name
- VAST-D II (NCT05554627)
- Testing
- Esketamine, Aripiprazole
- Where
- 26 sites in United States
- Sponsor
- VA Office of Research and Development
Depressive Disorder
Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy
The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting…
- Trial name
- NCT05388461
- Testing
- electroconvulsive therapy
- Where
- 2 sites in Norway
- Volunteers
- 600 people
- Sponsor
- Haukeland University Hospital
Depression, Depressive Disorder
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
To evaluate the equivalent efficacy of ultrabrief pulsewidth right unilateral electroconvulsive therapy versus bitemporal brief pulse electroconvulsive therapy in the treatment of depression and to evaluate the cognitive effects…
- Conditions
- Depression, Depressive Disorder, Treatment Resistant Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02238730
- Testing
- Ultrabrief Right Unilateral, Brief Pulse Bitemporal
- Sponsor
- Kaiser Permanente